Disc Medicine secures up to $200M non-dilutive debt facility from Hercules Capital

Disc Medicine, Inc.

$200M senior secured term loan facility from Hercules Capital; $30M drawn at closing.
Up to $80M additional available at Disc's sole discretion through second-half 2026.
Remaining $90M subject to milestone achievement or lender consent.
Interest-only for at least 48 months, extendable to 60 months; matures November 2029.
Proceeds to support bitopertin EPP confirmatory trial, DISC-0974 MF/NDD-CKD studies, and DISC-3405 PV trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.